+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-08-11Number of Pages: 131

Kaposi Sarcoma Market (Treatment - Chemotherapy (Liposomal Anthracyclines, Alkaloids), Immunotherapy, HAART); Distribution Channel - Hospitals, Cancer Research Institutes, Multispecialty Clinics,Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Kaposi Sarcoma Market: Snapshot

According to the U.S. Centers for Disease Control and Prevention, Kaposi sarcoma (KS) is considered to be an AIDS-defining disease, indicating that patients with KS go on to develop AIDS. The incidence of Kaposi sarcoma was reportedly high in homosexual men with HIV.

The market for Kaposi sarcoma is characterized by the increasing number of domestic players playing an important role in their respective regional markets. Given the patent expiry of most drugs in the KS market, there is immense scope for players of generic as well as branded drugs to establish a strong foothold in the coming years. The global Kaposi sarcoma market is projected to rise from US$118.5 mn in 2015 to reach US$143.2 mn in 2024 at a modest CAGR of 2.2% from 2016 to 2024.

 

kaposi-sarcoma-market

 

Adoption of Chemotherapy on the Rise in spite of High Cost

Chemotherapy, immunotherapy, and antiretroviral therapy (HAART) are the key treatment methods for Kaposi sarcoma. In 2015, HAART therapy emerged as the leading segment owing to the high incidence of AIDS-related Kaposi sarcoma globally. HAART therapy includes the combination of reverse transcriptase (RT) inhibitors, fusion inhibitors, and protease inhibitors.

Chemotherapy is likely to grow at the fastest pace during the forecast period from 2016 to 2024 due to the high cost of the treatment and the increasing adoption by immunocompetent patients. The leading chemotherapy drugs include paclitaxel, docetaxel, liposomal doxorubicin and daunorubicin, bleomicin, and vincristine.

Immunotherapy consists of interferon alfa, which is the first biological drug approved by the US FDA to for the treatment of Kaposi sarcoma. Patients with good immune functions show effectiveness; however, immunocompromised patients rarely respond to this therapy. Hence, it therapy accounted for the least share in the global market. The high cost of the therapy is a deterrent to patients in developing regions such as Asia Pacific and the Middle East and Africa and this limits its adoption. A limited number of approved biologics is also a prominent factor restraining the growth of the immunotherapy segment.

North America Leads Global Market despite Lower Incidence Rate of Kaposi Sarcoma

Geographically, the Kaposi sarcoma market has been segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa.

North America contributed to the major share in the Kaposi sarcoma market in 2015 due to the presence of key market players and the increasing cost of drugs. The growth of the market is also driven by the easy availability of drugs and a high diagnosis rate of the malignancy. The incidence of Kaposi sarcoma in the region is comparatively low and less than 10% of the population is considered to be affected by the cancer. According to Globocan, the incidence of KS in the U.S. was 0.1% of the total cancer incidence in 2012. However, North America has been witnessing a shortage in the drug supply needed for the treatment of KS, leading to a widening demand-supply gap. This is predicted to have a negative impact on the market.

The Middle East and Africa is expected to expand at the highest CAGR during the forecast period owing to the high incidence and prevalence of KS in Eastern Africa. This trend is consistent with the geographic variations of the HIV/AIDS epidemic. According to Globocan, the incidence of Kaposi sarcoma in Eastern Africa in 2012 was 10.2% of the total cancer incidence in the region. Despite the high incidence of endemic Kaposi sarcoma and HIV/AIDS associated KS, the lack of awareness among the people, late presentation of the disease, the high cost of treatment, and unavailability of treatment are some of the factors likely to impede the growth of the Middle East and Africa market.

Key players operating in the global Kaposi sarcoma market include Bristol Myers Squibb, Eli Lilly and Co., Hoffman-La Roche, Inc., GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., and Schering Plough Corporation (Merck & Co., Inc.).

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights   

2. Assumptions and Research Methodology

3. Executive Summary: Global Kaposi sarcoma market

4. Market Overview
     4.1. Introduction 
     4.2. Key market indicators
     4.3. Regulatory scenario
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunities
     4.5. Value Chain Analysis

5. Global Kaposi Sarcoma Market, by Treatment 
     5.1. Key Findings 
     5.2. Global Kaposi Sarcoma Market, by Type of Treatment, (US$ Mn), 2014–2024
            5.2.1. Chemotherapy
                    5.2.1.1. Liposomal Anthracyclines
                    5.2.1.2. Alkaloids
            5.2.2. Immunotherapy
            5.2.3. HAART
     5.3. Global Kaposi Sarcoma Market Attractiveness, by Treatment, 2015

6. Global Kaposi Sarcoma Market, by Distribution Channel
     6.1. Global Kaposi Sarcoma Market, by Distribution Channel, (US$ Mn), 2014–2024
            6.1.1. Hospitals
            6.1.2. Cancer Research Institutes
            6.1.3. Multispecialty Clinics
            6.1.4. Ambulatory Surgical Centers
     6.2. Global Kaposi Sarcoma Market Attractiveness, by Distribution Channel, 2015

7. Global Kaposi Sarcoma Market, by Region
     7.1. Global Kaposi Sarcoma Market, by Region, (US$ Mn), 2014–2024
            7.1.1. North America
            7.1.2. Europe
            7.1.3. Asia Pacific
            7.1.4. Latin America
            7.1.5. Middle East and Africa
     7.2. Global Kaposi Sarcoma Market Attractiveness, by Region, 2015

8. Global Kaposi Sarcoma Market, Pipeline Analysis 
     8.1. Overview
     8.2. List of Early Stage Drug Candidates 

9. North America Kaposi Sarcoma Market
     9.1. North America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
            9.1.1. Chemotherapy 
            9.1.2. Immunotherapy 
            9.1.3. HAART
     9.2. North America Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
            9.2.1. Hospitals
            9.2.2. Cancer Research Institutes
            9.2.3. Multispecialty Clinics
            9.2.4. Ambulatory Surgical Centers
     9.3. North America Kaposi Sarcoma Market, by Country, (US$), 2014–2024
            9.3.1. U.S.
            9.3.2. Canada
     9.4. Market Attractiveness, by Type of Treatment, 2015
     9.5. Market Attractiveness, by Country, 2015

10. Europe Kaposi Sarcoma Market
     10.1. Europe Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
            10.1.1. Chemotherapy 
            10.1.2. Immunotherapy 
            10.1.3. HAART
     10.2. Europe Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
            10.2.1. Hospitals
            10.2.2. Cancer Research Institutes
            10.2.3. Multispecialty Clinics
            10.2.4. Ambulatory Surgical Centers
     10.3. EuropeKaposi Sarcoma Market, by Country, (US$), 2014–2024
            10.3.1. U.K.
            10.3.2. Germany
            10.3.3. Rest of Europe
     10.4. Market Attractiveness, by Type of Treatment, 2015
     10.5. Market Attractiveness, by Country, 2015

11. Asia Pacific Kaposi Sarcoma Market
     11.1. Asia Pacific Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
            11.1.1. Chemotherapy 
            11.1.2. Immunotherapy 
            11.1.3. HAART
     11.2. Asia Pacific Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
            11.2.1. Hospitals
            11.2.2. Cancer Research Institutes
            11.2.3. Multispecialty Clinics
            11.2.4. Ambulatory Surgical Centers
     11.3. Asia Pacific Kaposi Sarcoma Market, by Country, (US$), 2014–2024
            11.3.1. China
            11.3.2. Japan
            11.3.3. India
            11.3.4. Australia
            11.3.5. Rest of Asia Pacific
     11.4. Market Attractiveness, by Type of Treatment, 2015
     11.5. Market Attractiveness, by Country, 2015

12. Latin America Kaposi Sarcoma Market
     12.1. Latin America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
            12.1.1. Chemotherapy 
            12.1.2. Immunotherapy 
            12.1.3. HAART
     12.2. Latin America Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
            12.2.1. Hospitals
            12.2.2. Cancer Research Institutes
            12.2.3. Multispecialty Clinics
            12.2.4. Ambulatory Surgical Centers
     12.3. Latin America Kaposi Sarcoma Market, by Country, (US$), 2014–2024
            12.3.1. Brazil
            12.3.2. Mexico
            12.3.3. Rest of Latin America
     12.4. Market Attractiveness, by Type of Treatment, 2015
     12.5. Market Attractiveness, by Country, 2015

13. Middle East and Africa Kaposi Sarcoma Market
     13.1. Middle East and Africa Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
            13.1.1. Chemotherapy 
            13.1.2. Immunotherapy 
            13.1.3. HAART
     13.2. Middle East and Africa Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
            13.2.1. Hospitals
            13.2.2. Cancer Research Institutes
            13.2.3. Multispecialty Clinics
            13.2.4. Ambulatory Surgical Centers
     13.3. Middle East and Africa Kaposi Sarcoma Market, by Country, (US$), 2014–2024
            13.3.1. U.A.E.
            13.3.2. South African Republic 
            13.3.3. Rest of Middle East and Africa
     13.4. Market Attractiveness, by Type of Treatment, 2015
     13.5. Market Attractiveness, by Country, 2015

14. Global Kaposi Sarcoma Market Analysis, By Services
     14.1. Radiation Therapy
     14.2. Surgery 

15. Competitive Landscape
     15.1. Growth-Share Matrix of Companies, 2015
     15.2. Market Share Analysis, 2015
     15.3. Company Profiles
            15.3.1. Bristol-Myers Squibb Company
                    15.3.1.1. Company Overview
                    15.3.1.2. Business Overview
                    15.3.1.3. Product Portfolio
                    15.3.1.4. Financial Overview
                    15.3.1.5. Recent Developments
            15.3.2. Eli Lilly and Company
                    15.3.2.1. Company Overview
                    15.3.2.2. Business Overview
                    15.3.2.3. Product Portfolio
                    15.3.2.4. Financial Overview
                    15.3.2.5. Recent Developments
            15.3.3. F. Hoffmann-La Roche Ltd.
                    15.3.3.1. Company Overview
                    15.3.3.2. Business Overview
                    15.3.3.3. Product Portfolio
                    15.3.3.4. Financial Overview
                    15.3.3.5. Recent Developments
            15.3.4. GlaxoSmithKline plc
                    15.3.4.1. Company Overview
                    15.3.4.2. Business Overview
                    15.3.4.3. Product Portfolio
                    15.3.4.4. Financial Overview
                    15.3.4.5. Recent Developments
            15.3.5. Johnson & Johnson
                    15.3.5.1. Company Overview
                    15.3.5.2. Business Overview
                    15.3.5.3. Product Portfolio
                    15.3.5.4. Financial Overview
                    15.3.5.5. Recent Developments
            15.3.6. Merck & Co., Inc.
                    15.3.6.1. Company Overview
                    15.3.6.2. Business Overview
                    15.3.6.3. Product Portfolio
                    15.3.6.4. Financial Overview
                    15.3.6.5. Recent Developments
            15.3.7. Pfizer, Inc.  
                    15.3.7.1. Company Overview
                    15.3.7.2. Business Overview
                    15.3.7.3. Product Portfolio
                    15.3.7.4. Financial Overview
                    15.3.7.5. Recent Developments

16. Recommendations

List of Figures

Figure 1 Market Segmentation
Figure 2 Global Kaposi Sarcoma Market Revenue by Type of Treatment, (US$ Mn), 2014–2024
Figure 3 Global Kaposi Sarcoma Market Revenue, by Distribution Channel, (US$ Mn), 2014–2024
Figure 4 Global Kaposi Sarcoma Market Revenue, by Geography, (US$ Mn), 2014–2024
Figure 5 Value Chain Analysis
Figure 6 Global Liposomal Anthracyclines Market for Kaposi Sarcoma, (US$ Mn), 2014–2024
Figure 7 Global Alkaloids Market, (US$ Mn), 2014–2024
Figure 8 Global Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
Figure 9 Global Kaposi Sarcoma Market Attractiveness, by Distribution Channel, 2015
Figure 10 Global Kaposi Sarcoma Market Attractiveness, by Region, 2015
Figure 11 North America Kaposi Sarcoma Market Attractiveness, by Type of Treatment, 2015
Figure 12 North America Kaposi Sarcoma Market Attractiveness, by Country, 2015
Figure 13 Europe Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
Figure 14 Europe Kaposi Sarcoma Market Attractiveness, by Country, 2015
Figure 15 Asia Pacific Kaposi Sarcoma Market Attractiveness, by Type of Treatment, 2015
Figure 16 Asia Pacific Kaposi Sarcoma Market Attractiveness, by Country, 2015
Figure 17 Latin America Kaposi Sarcoma Market Attractiveness, by Type of Treatment, 2015
Figure 18 Latin America Kaposi Sarcoma Market Attractiveness, by Country, 2015
Figure 19 Middle East and Africa Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
Figure 20 Middle East and Africa Kaposi Sarcoma Market Attractiveness, by Country, 2015
Figure 21 Growth Share Matrix, By Key Players (2015)
Figure 22 Market Share Analysis by Key Companies (Value %), 2015
Figure 23 Bristol-Myers Squibb Company Financial Overview (US$ Mn), 2013–2015
Figure 24 Bristol-Myers Squibb Company Revenues by Segment, 2015 (%)
Figure 25 Eli Lilly and Company Financial Overview (US$ Mn), 2013–2015
Figure 26 Eli Lilly and Company Human Pharmaceutical Products sub-segment revenues 2015 (%)
Figure 27  F. Hoffmann-La Roche Ltd. Financial Overview (US$ Mn), 2013–2015
Figure 28 F. Hoffmann-La Roche Ltd. Pharmaceutical sub-segment revenues 2015 (%)
Figure 29 GlaxoSmithKline plc Financial Overview (US$ Mn), 2013–2015 
Figure 30 Johnson & Johnson Financial Overview (US$ Mn), 2013–2015
Figure 31 Johnson & Johnson Pharmaceutical sub-segment revenues, 2015 (%)
Figure 32 Merck & Co., Inc. Financial Overview (US$ Mn), 2013–2015
Figure 33 Merck & Co., Inc. Pharmaceutical sub-segment revenues, 2015 (%)
Figure 34 Pfizer, Inc. Financial Overview (US$ Mn), 2013–2015
Figure 35 Pfizer, Inc. Global Vaccines, Oncology, and Consumer Healthcare sub-segment Revenues 2015 (%)

List of Tables

Table 1 Global Kaposi Sarcoma Market, By Type of Treatment Snapshot (2014 - 2024)
Table 2 Global Kaposi Sarcoma Market, By Distribution Channel, Snapshot (2014 - 2024)
Table 3 Global Kaposi Sarcoma Market, By Geography Snapshot (2014 - 2024)
Table 4 Global Kaposi Sarcoma Market, by Type of Treatment, (US$ Mn), 2014–2024
Table 5 Global Kaposi Sarcoma Market, by Distribution Channel, (US$ Mn), 2014–2024
Table 6 Global Kaposi Sarcoma Market, by Region, (US$ Mn), 2014–2024
Table 7 Pipeline Analysis
Table 8 North America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 9 North America Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–    2024
Table 10 North America Kaposi Sarcoma Market, by Country, (US$), 2014–2024
Table 11 Europe Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 12 Europe Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
Table 13 Europe Kaposi Sarcoma Market, by Country, (US$), 2014–2024
Table 14 Asia Pacific Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 15 Asia Pacific Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
Table 16 Asia Pacific Kaposi Sarcoma Market, by Country, (US$), 2014–2024
Table 17 Latin America Kaposi Sarcoma Market, by Type of Treatment (US$), 2014–2024
Table 18 Latin America Kaposi Sarcoma Market, by Distribution Channel (US$), 2014–2024
Table 19 Latin America Kaposi Sarcoma Market, by Country (US$), 2014–2024
Table 20 Middle East & Africa Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
Table 21 Middle East & Africa Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
Table 22 Middle East & Africa Kaposi Sarcoma Market, by Country, (US$), 2014–2024
Table 23 Radiotherapy and Surgery (Average cost and Number of procedures)

Kaposi sarcoma is a soft tissue sarcoma that develops in connective tissues, blood vessels, fibrous tissues, and muscles. It is a malignant, multi-centric, neoplastic vascular proliferation, characterized by the development of bluish-red cutaneous nodules on the feet. According to the U.S. Center for Disease Control and Prevention (CDC), Kaposi sarcoma is considered an acquired immune deficiency syndrome (AIDS) defining disease. This report analyzes the current and future prospects of the Kaposi sarcoma market based on type of treatment, distribution channel, and geography.

The report is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of major Kaposi sarcoma therapies in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, and various international and national databases. The report provides estimated market size in terms of US$ Mn for each treatment method, distribution channel, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each treatment method was calculated by considering number of patients, average cost of the drugs, trends in the industry, distribution channel trends, and adoption rate of therapy across all the geographies. The revenues generated from services, including surgery and radiation therapy were calculated based on the costs and average number of procedures.

The market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of treatment, distribution channel, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints, and opportunities that influence the Kaposi sarcoma market in the current and future scenario. The report provides the list of drugs in various stages of clinical trials, which are expected to shape the future course of the market, through pipeline analysis. The report also provides value chain analysis of the market that describes the sequence of activities from drug manufacturing to the final destination, which is the end user.

Market share analysis is provided to highlight percentage share of the major players operating in the market. All these factors will help market players to decide business strategies and plans to strengthen their position in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Market forecast for major countries in these regions have also been provided for the forecast period.

In addition, this report includes a list of recommendations to aid new entrants and established players in taking strategic initiatives to strengthen their presence in the market. The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the Kaposi sarcoma market report are Bristol - Myers Squibb, Eli Lilly and Co., Hoffman-La Roche, Inc., GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., and Schering Plough Corporation (Merck & Co., Inc.)

The global Kaposi Sarcoma market has been segmented as follows:

  • Kaposi Sarcoma Market, By Type of Treatment
    • Chemotherapy
      • Liposomal Anthracyclines
      • Alkaloids
    • Immunotherapy
    • HAART
       
  • Kaposi Sarcoma Market, By Distribution Channel
    • Hospitals
    • Cancer Research Institutes
    • Multispecialty Clinics
    • Ambulatory Surgical Centers
       
  • Kaposi Sarcoma Market, By Geography
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East and Africa
      • U.A.E.
      • South Africa
      • Rest of Middle East and Africa


 
 
Back To Top